Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.
Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.
Theratechnologies (NASDAQ: THTX) ha tenuto la sua assemblea annuale virtuale degli azionisti il 29 maggio 2025. Durante l'incontro, gli azionisti hanno eletto otto amministratori nel Consiglio di Amministrazione della Societ脿 per un mandato di un anno. Tutti i candidati proposti sono stati eletti con tassi di approvazione compresi tra 77,98% e 84,03%. Joseph Arena ha ottenuto il maggior sostegno degli azionisti con il 84,03% dei voti favorevoli, mentre Dawn Svoronos ha ricevuto il 77,98% dei voti a favore.
Inoltre, gli azionisti hanno nominato KPMG LLP come revisori contabili della Societ脿 per l'esercizio in corso e hanno approvato un piano omnicomprensivo di incentivi a lungo termine a beneficio degli amministratori, dirigenti e dipendenti della Societ脿 e delle sue controllate.
Theratechnologies (NASDAQ: THTX) celebr贸 su junta anual virtual de accionistas el 29 de mayo de 2025. Durante la reuni贸n, los accionistas eligieron a ocho directores para la Junta de la Compa帽铆a por un per铆odo de un a帽o. Todos los candidatos propuestos fueron elegidos con tasas de aprobaci贸n que oscilaron entre 77,98% y 84,03%. Joseph Arena recibi贸 el mayor apoyo de los accionistas con un 84,03% de votos a favor, mientras que Dawn Svoronos obtuvo un 77,98% de votos favorables.
Adem谩s, los accionistas nombraron a KPMG LLP como auditores de la Compa帽铆a para el a帽o fiscal actual y aprobaron un plan integral de incentivos a largo plazo que beneficia a los directores, ejecutivos y empleados de la Compa帽铆a y sus subsidiarias.
Theratechnologies (NASDAQ: THTX)電� 2025雲� 5鞗� 29鞚� 鞐半 臧�靸� 欤检＜齑濏殞毳� 臧滌禍頄堨姷雼堧嫟. 須岇潣鞐愳劀 欤检＜霌れ潃 須岇偓 鞚挫偓須岇棎 1雲� 鞛勱赴鞚� 8氇呾潣 鞚挫偓毳� 靹犾稖頄堨姷雼堧嫟. 鞝滌晥霅� 氇摖 頉勲炒鞛愱皜 77.98%鞐愳劀 84.03% 靷澊鞚� 鞀轨澑鞙 靹标车鞝侅溂搿� 靹犾稖霅橃棃鞀惦媹雼�. Joseph Arena臧� 84.03%鞚� 彀劚響滊 臧�鞛� 雴掛潃 欤检＜ 歆�歆�毳� 氚涭晿鞙茧┌, Dawn Svoronos電� 77.98%鞚� 彀劚響滊ゼ 氚涭晿鞀惦媹雼�.
霕愴暅, 欤检＜霌れ潃 KPMG LLP毳� 鞓暣 須岅硠鞐半弰 須岇偓 臧愳偓鞚胳溂搿� 鞛勲獏頃橁碃, 須岇偓 氚� 鞛愴殞靷潣 鞚挫偓, 鞛勳洂, 歆侅洂霌れ潉 鞙勴暅 膦呿暕 鞛リ赴 鞚胳劶韹半笇 瓿勴殟鞚� 鞀轨澑頄堨姷雼堧嫟.
Theratechnologies (NASDAQ : THTX) a tenu son assembl茅e annuelle virtuelle des actionnaires le 29 mai 2025. Lors de cette r茅union, les actionnaires ont 茅lu huit administrateurs au conseil d'administration de la soci茅t茅 pour un mandat d'un an. Tous les candidats propos茅s ont 茅t茅 茅lus avec des taux d'approbation allant de 77,98 % 脿 84,03 %. Joseph Arena a obtenu le plus grand soutien des actionnaires avec 84,03 % des voix en sa faveur, tandis que Dawn Svoronos a re莽u 77,98 % des votes favorables.
De plus, les actionnaires ont nomm茅 KPMG LLP en tant que commissaires aux comptes de la soci茅t茅 pour l'exercice en cours et ont approuv茅 un plan global d'incitation 脿 long terme b茅n茅ficiant aux administrateurs, dirigeants et employ茅s de la soci茅t茅 et de ses filiales.
Theratechnologies (NASDAQ: THTX) hielt am 29. Mai 2025 seine j盲hrliche virtuelle Hauptversammlung ab. W盲hrend der Versammlung w盲hlten die Aktion盲re acht Direktoren f眉r den Vorstand des Unternehmens f眉r eine einj盲hrige Amtszeit. Alle vorgeschlagenen Kandidaten wurden mit Zustimmungsraten von 77,98 % bis 84,03 % erfolgreich gew盲hlt. Joseph Arena erhielt mit 84,03 % die h枚chste Zustimmung der Aktion盲re, w盲hrend Dawn Svoronos 77,98 % der positiven Stimmen erhielt.
Zus盲tzlich bestellten die Aktion盲re KPMG LLP als Wirtschaftspr眉fer des Unternehmens f眉r das laufende Gesch盲ftsjahr und genehmigten einen umfassenden langfristigen Anreizplan zugunsten der Direktoren, F眉hrungskr盲fte und Mitarbeiter des Unternehmens und seiner Tochtergesellschaften.
- None.
- None.
MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (鈥淭heratechnologies鈥� or the 鈥淐ompany鈥�) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company鈥檚 Board of Directors for a one-year term, appointed KPMG LLP as the Company鈥檚 auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.
All candidates proposed for the position of director were elected in the following proportion:
| 听 | FOR | % FOR | ABSTENTION | % ABSTENTION |
| Joseph Arena | 20,473,944 | 3,890,222 | ||
| Frank Holler | 19,089,786 | 5,274,380 | ||
| Paul L茅vesque | 19,027,772 | 5,336,394 | ||
| Andrew Molson | 19,066,145 | 5,298,021 | ||
| Dawn Svoronos | 18,998,230 | 5,365,936 | ||
| Elina Tea | 19,163,502 | 5,200,664 | ||
| Dale Weil | 19,005,768 | 5,358,398 | ||
| Jordan Zwick | 19,618,725 | 4,745,441 | ||
| 听 | 听 | 听 | 听 | 听 |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at听, on SEDAR+ at听听and on EDGAR at听. Follow Theratechnologies on听听and听听(formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
514-336-7800
FAQ
Who was elected to Theratechnologies (THTX) Board of Directors in 2025?
What was the highest approval rate for THTX board members in the 2025 election?
What additional matters were approved at Theratechnologies' 2025 annual meeting?
How was Theratechnologies' 2025 annual shareholder meeting conducted?
